Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 46 (5) , 592-599
Abstract
Cisplatin is a cytostatic drug used for treatment of solid organ tumors. The main adverse effect is organic cation transporter 2 (OCT2)–mediated nephrotoxicity, observed in 30% of patients. The contribution of other renal drug transporters is elusive. Here, cisplatin-induced toxicity was evaluated in human-derived conditionally immortalized proximal tubule epithelial cells (ciPTEC) expressing renal drug transporters, including OCT2 and organic anion transporters 1 (OAT1) or 3 (OAT3). Parent ciPTEC demonstrated OCT2-dependent cisplatin toxicity (TC50 34 ± 1 μM after 24-hour exposure), as determined by cell viability. Overexpression of OAT1 and OAT3 resulted in reduced sensitivity to cisplatin (TC50 45 ± 6 and 64 ± 11 μM after 24-hour exposure, respectively). This effect was independent of OAT-mediated transport, as the OAT substrates probenecid and diclofenac did not influence cytotoxicity. Decreased cisplatin sensitivity in OAT-expressing cells was associated directly with a trend toward reduced intracellular cisplatin accumulation, explained by reduced OCT2 gene expression and activity. This was evaluated by Vmax of the OCT2-model substrate ASP+ (23.5 ± 0.1, 13.1 ± 0.3, and 21.6 ± 0.6 minutes−1 in ciPTEC-parent, ciPTEC-OAT1, and ciPTEC-OAT3, respectively). Although gene expression of cisplatin efflux transporter multidrug and toxin extrusion 1 (MATE1) was 16.2 ± 0.3-fold upregulated in ciPTEC-OAT1 and 6.1 ± 0.7-fold in ciPTEC-OAT3, toxicity was unaffected by the MATE substrate pyrimethamine, suggesting that MATE1 does not play a role in the current experimental set-up. In conclusion, OAT expression results in reduced cisplatin sensitivity in renal proximal tubule cells, explained by reduced OCT2-mediated uptake capacity. In vitro drug-induced toxicity studies should consider models that express both OCT and OAT drug transporters.Keywords
This publication has 60 references indexed in Scilit:
- The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut–liver–kidney axisJournal of Biological Chemistry, 2017
- Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving CisplatinInternational Journal of Molecular Sciences, 2017
- Bardoxolone methyl modulates efflux transporter and detoxifying enzyme expression in cisplatin-induced kidney cell injuryToxicology Letters, 2016
- Species differences in drug transporters and implications for translating preclinical findings to humansExpert Opinion on Drug Metabolism & Toxicology, 2012
- Linkage of Organic Anion Transporter-1 to Metabolic Pathways through Integrated “Omics”-driven Network and Functional AnalysisJournal of Biological Chemistry, 2011
- Transcriptional Regulation of Renal Cytoprotective Genes by Nrf2 and Its Potential Use as a Therapeutic Target to Mitigate Cisplatin-Induced NephrotoxicityThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Regulation of human organic cation transporter hOCT2 by PKA, PI3K, and calmodulin-dependent kinasesAmerican Journal of Physiology-Renal Physiology, 2003
- Transport of organic anions across the basolateral membrane of proximal tubule cells2003
- Mechanism of Electrogenic Cation Transport by the Cloned Organic Cation Transporter 2 from RatJournal of Biological Chemistry, 2000
- Stability of cisplatin and its monohydrated complex in blood, plasma and ultrafiltrate — implications for quantitative analysisJournal of Pharmaceutical and Biomedical Analysis, 1995